InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,737.03
(
0.55%
)
US TECH 100
19,511.20
(
0.81%
)
Dow Jones
42,109.97
(
0.83%
)
Brent Oil
73.11
(
-1.22%
)
Bitcoin
69,240.81
(
-1.38%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120655
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 61472

Wednesday, 04/16/2008 5:33:49 PM

Wednesday, April 16, 2008 5:33:49 PM

Post# of 253509
Re: Notes on US HIV Market from GILD CC

The fact that the Atripla’s Rx share is almost as large as Truvada’s molecule share (which includes the Rx share of Atripla + the Rx share of standalone Truvada) shows the immense importance of formulating an HIV regimen into a single qD pill.

In other words, Atripla is blowing away Truvada+Reyataz and Truvada+Kaletra despite the fact that Reyataz and Kaletra are arguably as safe and effective as Sustiva (the non-Truvada component of Atripla) when combined with Truvada.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up